-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $48

Benzinga·02/25/2026 11:51:49
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $45 to $48.